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Abstract
The αvβ3 integrin is expressed on proliferating endothelial cells and some cancer cells, but its expression on ovar-
ian cancer cells and its potential as a therapeutic target are unknown. In this study, expression of the αvβ3 integrin
on ovarian cancer cell lines and murine endothelial cells was tested, and the effect of a fully humanized mono-
clonal antibody against αvβ3, Abegrin (etaracizumab), on cell invasion, viability, tumor growth, and the Akt pathway
were examined in vitro and in vivo. We found that etaracizumab recognizes αvβ3 on the ovarian cancer cell lines
SKOV3ip1, HeyA8, and A2780ip2 (at low levels) but not on murine endothelial cells. Etaracizumab treatment de-
creased ovarian cancer proliferation and invasion. In vivo, tumor-bearing mice treated with etaracizumab alone
gave variable results. There was no effect on A2780ip2 growth, but a 36% to 49% tumor weight reduction in
the SKOV3ip1 and HeyA8 models was found (P < .05). However, combined etaracizumab and paclitaxel was
superior to paclitaxel in the SKOV3ip1 and A2780ip2 models (by 51-73%, P < .001) but not in the HeyA8 model.
Treatment with etaracizumab was then noted to decrease p-Akt and p-mTOR in SKOV3ip1, but not in HeyA8, which
is Akt-independent. Tumors resected after therapy showed that etaracizumab treatment reduced the proliferating
cell nuclear antigen index but not microvessel density. This study identifies tumor cell αvβ3 integrin as an attractive
target and defines the Akt pathway as a predictor of response to function-blocking antibody.
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Introduction
Integrins are a family of cell surface receptors that are primarily re-
sponsible for exchanging information between cells and the sur-
rounding extracellular matrix (ECM) [1]. They are heterodimers
composed of 1 of 10 α subunits and 1 of 8 β subunits, and each
subtype has specificity for different ECM proteins. In response to
binding components of the ECM, such as collagen, fibronectin, or
vitronectin, signals are generated within the cell that can affect
growth, migration, invasion differentiation, and survival [2,3]. As
more is learned about the importance of a tumor cell’s microenviron-
ment to survival and invasive potential, integrins are seen to play an
important role in tumor biology and may serve as useful targets to
tumor therapy.
The αvβ3 integrin [4] is preferentially expressed on developing,
rather than mature vasculature, and is considered the most important
integrin for angiogenesis [5]. Its primary ligand is vitronectin, but it
also interacts with fibrinogen, fibronectin, and thrombospondin
[6,7]. Furthermore, associations have been found between αvβ3
and matrix metalloproteinase 2, platelet-derived growth factor, insu-
lin, and vascular endothelial growth factor receptor 2 (VEGFR-2)
[8–11]. In a self-promoting loop, VEGF, one of the more potent stim-
ulators of angiogenesis [12,13], up-regulates αvβ3 expression and
increases affinity for its ligands [14], which in turn interacts with
VEGFR-2 to further amplify VEGF [15]. Administration of a mouse
monoclonal antibody against αvβ3 (LM609) was shown to disrupt
tumor-induced angiogenesis on chick chorioallantoic membrane
(CAM) [5], and in subsequent studies, disrupt tumor-associated vas-
culature and induce tumor regression without significant adverse
effects on established, mature blood vessels. Subsequent studies of
the LM609 antibody showed tumor growth inhibition in preclini-
cal mouse models of melanoma [16,17] and breast cancer [18],
and synergy with immunotherapy in neuroblastoma [19].
More recently, αvβ3 expression has been demonstrated on meta-
static human melanoma, breast, prostate, and glioblastoma tumor
cells, where its expression contributes to malignant phenotype. A fully
humanized antibody targeted to αvβ3 has demonstrated encouraging
activity (etaracizumab, Abegrin; MedImmune, Inc., Gaithersburg,
MD) [20]. The αvβ3 integrin has been studied in ovarian cancer, with
targeting by either antibodies or small molecule inhibitors shown to
inhibit migration, adhesion, motility, angiogenesis, and proliferation
in vitro [11,21–24]. The αv subunit has been found in malignant ef-
fusions and solid tumors from ovarian cancer patients [25]. However,
the biologic significance of αvβ3 targeting is not fully understood. The
aim of this study was to determine the effects of αvβ3 on ovarian can-
cer cell line invasion, proliferation, vascularization, and tumor growth
in an in vivo orthotopic model of advanced ovarian cancer. Examining
several cell lines in vivo, we have also identified molecular correlates of
anti-αvβ3 therapy. These findings support the use of etaracizumab as
therapy for ovarian cancer and demonstrate the benefit of tailoring
therapy based on an individual’s tumor biology.
Materials and Methods
Cell Lines and Culture
The ovarian cancer cell lines HeyA8, SKOV3ip1, A2780, and
A2780ip2 [26,27] were maintained in RPMI 1640 supplemented
with 15% FBS and 0.1% gentamicin sulfate (Gemini Bioproducts,
Calabasas, CA). The A2780ip2 line was developed by culture of tu-
mors grown in the mouse intraperitoneal (IP) cavity after IP injection
of A2780, through two passes. Endothelial cells isolated from the
mesentery or ovary of the immortomouse were a kind gift from
Dr. Robert Langley [28] and maintained in DMEM with 10%
FBS. These cells proliferate indefinitely by means of SV40 transfor-
mation at 33°C. However, when switched to 37°C, SV40 expression
is turned off, and cells proliferate for only a few more cycles [28].
When using these cells, they were kept at 37°C for 48 hours before
any experiments were performed, to allow elimination of SV40 ex-
pression. All in vitro experiments were conducted at 60% to 80%
confluence, unless otherwise specified. For vitronectin-coating ex-
periments, 20 μg/ml vitronectin (Chemicon, Temecula, CA) in
PBS (or PBS alone) was added to culture vessels and incubated at
37°C overnight. Afterwards, vitronectin/PBS was removed and re-
placed with 1% bovine serum albumin in PBS for 1 hour at 37°C.
This was then removed immediately before plating cells for an experi-
ment. For in vivo injection, cells were trypsinized and centrifuged
at 1000 rpm for 7 minutes at 4°C, washed twice, and reconstituted
in Hank’s balanced salt solution (Gibco, Carlsbad, CA) at a concen-
tration of 5 × 106 cells/ml for 200-μl IP injections of 1 × 106 cells.
Flow Cytometry
Cells growing in monolayer culture at 60% to 80% confluence
were trypsinized with EDTA and washed in PBS. Cells were re-
constituted to equal 5 × 106 cell/ml, and 200 μl was incubated with
1 μg/ml anti-αvβ3 antibody (LM609; Upstate, San Francisco, CA)
with gentle rotation at 4°C for 30 minutes. Cells were spun at
2000 rpm for 5 minutes, washed twice with PBS, and reincubated
with antimouse IgG-FITC (Upstate) at 4°C for 30 minutes. Cells
were washed with PBS and reconstituted in 1 ml of PBS for imme-
diate reading with an EPICS XL-MCL flow cytometer (Beckman
Coulter Inc., Miami, FL).
Immunoprecipitation and Western Blot
Immunoblot detection of αv and β3 integrin subunits was per-
formed using a modified immunoprecipitation technique that not
only allowed detection of both αv and β3 together in a single sample
but also allowed detection of other integrin subunits associated with
either αv or β3. Cells in monolayer culture were labeled with biotin,
and cell lysates were prepared by washing cells with PBS followed by
incubation in modified RIPA lysis buffer (50 mM Tris, 150 mM
NaCl, 1% Triton, 0.5% deoxycholate plus 25 μg/ml leupeptin,
10 μg/ml aprotinin, 2 mM EDTA, and 1 mM sodium orthovana-
date; Sigma Chemical Co., St. Louis, MO) for 10 minutes at 4°C.
Cells were scraped from plates and centrifuged at 13,000 rpm for
20 minutes at 4°C, and the supernatant was stored at −80°C. Protein
concentrations were determined using a BCA Protein Assay Reagent
kit (Pierce Biotechnology, Rockford, IL), and samples were separated
for αv or β3 testing. Protein (300 μg) was immunoprecipitated with
either anti-αv antibody (Chemicon, Temecula, CA), anti-β3 antibody
(Cell Signaling), or control IgG antibody in PBS for 30 minutes at
4°C, followed by protein A sepharose beads 50% slurry for 30 minutes
at 4°C. Protein was eluted from beads in reducing Laemmli buffer, and
were beads separated from the lysate by centrifugation. Samples were
subjected to 10% SDS-PAGE separation and transferred to a nitrocel-
lulose membrane by semidry electrophoresis (Bio-Rad Laboratories,
Hercules, CA), and biotin was detected with 1.0 μg/ml HRP-conjugated
antimouse IgG (Amersham, Piscataway, NJ), and developed using en-
hanced chemiluminescence detection kit (ECL; Pierce).
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For immunoblot detection of other proteins, cells were collected
in modified RIPA lysis buffer as above (without prior incubation
with biotin). After BCA quantification, 50 μg of protein lysate in
Laemmli buffer was subjected to 10% SDS-PAGE separation and
transferred to a nitrocellulose membrane. After blocking the mem-
brane with 5% milk in TBS–0.1% Tween 20 (TBS-T), they were
incubated with the appropriate primary antibody overnight at 4°C
(anti–phosphorylated Akt, anti–total Akt2, anti–total Akt1, anti–
phosphorylated PI3K, and anti–phosphorylated mTOR from Cell
Signaling; and anti–β-actin from Sigma). After washing with TBS-T,
appropriate secondary antibody was applied (anti–mouse IgG-HRP
and anti–rabbit IgG-HRP from Amersham) for 1 hour at room tem-
perature; the membrane was washed with TBS-T and developed with
ECL as above.
Cell Invasion
Invasion through a human-defined matrix was assessed using the
Membrane Invasion Culture System (MICS). Briefly, this system
consists of an upper chamber loaded with cells and a lower chamber
with fibroblast-derived chemoattractants into which cells may in-
vade, through a semiporous membrane coated with laminin, colla-
gen, vitronectin, and fibronectin. A total of 100,000 cells in media
containing control human IgG (10 μg/ml) or etaracizumab (1 or
10 μg/ml) were loaded into the upper chamber and allowed to invade
for 24 hours. The cells migrating into the lower chamber were col-
lected, fixed onto a membrane, stained, and counted by microscopy
by an examiner blinded to the experimental group.
Cell Viability Assay
To determine effects on cell proliferation and sensitivity to docetaxel,
2000 cells were plated in each well of a 96-well plate, and experi-
mental conditions were set in triplicate 24 hours after cell plating.
Before plating cells, plates were either uncoated or coated with vitro-
nectin (the primary αvβ3 ligand) by incubating plates in 50 μl of
10 μg/ml vitronectin (Chemicon) for 2 hours at room temperature,
followed by the removal of vitronectin solution and storage at 4°C
for 12 hours. To assess viability after etaracizumab treatment, cells were
incubated with 200 μl of serum-containing growth media containing
increasing concentrations of etaracizumab. For docetaxel sensitivity ex-
periments, cells were exposed to increasing concentrations of docetaxel
with 25 μg/ml etaracizumab (one-time treatment) or 25 μg/ml of non-
specific human IgG (Jackson Laboratory, Bar Harbor, ME). Cell via-
bility was assessed by MTTassay after 5 to 7 days, at which time 50 μl
of 0.15% MTT (Sigma) was added to each well. After incubation for
2 hours at 37°C, the media/MTTwas removed, and cells were recon-
stituted in 100 μl of DMSO (Sigma). After shaking, the absorbance at
570 nm was recorded using a FALCON microplate reader (Becton
Dickinson Labware, Franklin Lakes, NJ). The IC50 was determined
by calculating the mean OD570 ([Max OD − Min OD] / 2 + Min
OD) and finding the docetaxel concentration at which this OD read-
ing intersected the dose-response curve.
Orthotopic In Vivo Model and Tissue Processing
Female athymic nude mice (NCr-nu) were purchased from the
National Cancer Institute – Frederick Cancer Research and Develop-
ment Center (Frederick, MD) and housed in specific pathogen-free
conditions. They were cared for in accordance with guidelines set
forth by the American Association for Accreditation of Laboratory
Animal Care and the U.S. Public Health Service Policy on Human
Care and Use of Laboratory Animals, and all studies were approved
and supervised by the UT MD Anderson Cancer Center Institu-
tional Animal Care and Use Committee. For long-term experiments
to assess tumor growth, therapy began 1 week after IP cell injection
of 1 × 106 cells (se the Cell Lines and Culture section). Therapy
consisted of four groups: 1) Control human IgG, 2) etaracizumab,
3) paclitaxel plus control IgG, or 4) paclitaxel plus etaracizumab.
Antibodies were diluted in PBS and injected intraperitoneally twice
per week, at a dose of 10 mg/kg, in a volume of 180 to 220 μl (de-
pending on mouse weight). Paclitaxel was diluted in PBS and in-
jected IP once a week, at a dose of 100 μg, in 200 μl. Mice were
monitored for adverse effects, and the experiment concluded if ani-
mals in any group began to appear moribund and required sacrifice
or if any tumor-bearing animal was found dead from tumor burden
(generally 4-5 weeks after cell injection). All animals in the experi-
ment were killed together by cervical dislocation. Mouse weight, tu-
mor weight, and distribution of tumor were recorded by examiners
blinded to experimental group. Tissue specimens were snap frozen
for lysate preparation, fixed in formalin for paraffin embedding,
and frozen in OCTmedia for frozen slide preparation.
Immunohistochemistry
Staining for proliferating cell nuclear antigen (PCNA) and CD31
was conducted on tumors collected at the conclusion of 4-week ther-
apy trials. Formalin-fixed, paraffin-embedded sections were deparaf-
finized by sequential washing with xylene, 100% ethanol, 95%
ethanol, 80% ethanol, and PBS. After antigen retrieval (described
below), endogenous peroxide was blocked with 3%H2O2 in methanol
for 5 minutes. After washing twice in PBS, slides were blocked with
5% normal horse serum and 1% normal goat serum in PBS for
15 minutes at room temperature, followed by incubation with pri-
mary antibody in blocking solution overnight at 4°C. After washing
twice with PBS, the appropriate secondary antibody conjugated to
horseradish peroxidase, in blocking solution, was added for 1 hour
at room temperature. HRP was detected with DAB (Phoenix Bio-
technologies, Huntsville, AL) substrate for 5 minutes, washed, and
counterstained with Gil No. 3 hematoxylin (Sigma) for 20 seconds.
Primary antibodies used included anti-CD31 (PECAM-1, rat IgG;
Pharmingen, San Jose, CA) and anti-PCNA (PC-10, mouse IgG;
Dako, Carpinteria, CA). Immunohistochemistry for PCNA was per-
formed on paraffin-embedded slides with antigen retrieval of microwave
heating for 5 minutes in 0.1 M citrate buffer, pH 6.0. Immunohisto-
chemistry for CD31 was performed on freshly cut tissue frozen in
OCT. These slides were fixed in cold acetone for 10 minutes and
did not require antigen retrieval.
Statistics
Continuous variables were compared with the Student’s t test (be-
tween two groups) or analysis of variance (for all groups) if normally
distributed and the Mann-Whitney rank sum test if nonparametric.
For in vivo therapy experiments, 10 mice in each group were used,
as directed by a power analysis to detect a 50% reduction in tumor size
(β error = 0.2). A P < .05 on 2-tailed testing was considered significant.
Results
The αvβ3 Integrin Is Expressed by Ovarian Cancer Cells
Although the αvβ3 integrin was initially thought to primarily be
expressed by proliferating and immature endothelial cells, it has also
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been found on some tumor cells [29–32]. To determine whether
ovarian cancer cell lines express αvβ3, we performed flow cytometry
(Figure 1A) and Western Blot (Figure 1B) analyses to detect protein
expression. The SKOV3ip1 and HeyA8 cell lines have prominent
αvβ3 recognition by the LM609 primary antibody, the murine anti-
body from which the fully humanized etaracizumab was derived and
shares the Fab′ construct. The A2780ip2 cell line has less promi-
nent expression, but a definite population with αvβ3 expression (es-
timated at 9.8% of cells, experiment repeated twice with identical
results). Furthermore, β3 expression was seen in A2780 lysate from
tumor samples collected at the conclusion of in vivo studies described
below, suggesting αvβ3 expression is up-regulated in vivo compared
to in vitro (data not shown). After immunoprecipitation with αv,
β3, or control IgG, presence of the αv subunit was prominent in
all three cell lines, and β3 expression was high in SKOV3ip1 and
HeyA8 but low in A2780. The presence of additional bands (com-
pared with IgG) with αv but not with β3 indicates that the αv sub-
unit forms heterodimers with β subunits other than β3 (though less
commonly), but the only α subunit that β3 forms a heterodimer with
is αv. The etaracizumab antibody does not interact with other in-
tegrins, including αvβ5 (data not shown). Importantly, the antibody
also does not recognize murine αvβ3, as reported previously [33] and
confirmed by FACS analysis of cultured murine endothelial cells
(Figure 1A).
Etaracizumab Inhibits In Vivo Tumor Growth in
an Orthotopic Mouse Model of Ovarian Cancer
We next examined whether treatment with etaracizumab could re-
duce tumor growth in an in vivo orthotopic mouse model of ad-
vanced ovarian cancer in all three cell lines (SKOV3ip1, A2780ip2,
and HeyA8). After IP cell injection, mice were randomized to four
treatment groups (n = 10 mice per group): 1) control human IgG,
10 mg/kg twice per week; 2) etaracizumab, 10 mg/kg twice per week;
3) paclitaxel, 100 μg weekly plus control IgG; or 4) paclitaxel plus
etaracizumab (given at doses listed above). All treatments were admin-
istered intraperitoneally. Animals were treated until mice in any group
became moribund, at which point all mice in an experiment were
killed (4-5 weeks). In the SKOV3ip1 model (Figure 2A), etaracizumab
alone reduced tumor growth by 48.8% compared to IgG (P = .041).
Paclitaxel, as previously seen in this model, reduced growth by 66%
(P < .01 vs IgG and P = .06 vs etaracizumab). The combination of
paclitaxel and etaracizumab significantly reduced growth by 83.3%
compared to control IgG alone (P < .001) and by 50.8% compared
to paclitaxel/IgG (P = .01). Etaracizumab alone, paclitaxel alone, and
Figure 1. Expression of αvβ3 in ovarian cancer cell lines. Recognition of the αvβ3 heterodimer was assessed first by flow cytometry, using
themurinemonoclonal antibody clone LM609 as primary antibody (A). This is the clone fromwhich the etaracizumab antibodywas derived
and shares identical Fab′ regions. There is a high expression of αvβ3 in the SKOV3ip1 and HeyA8 lines, and expression in a smaller pop-
ulation in A2780ip2. LM609 does not bind to αvβ3 in murine endothelial cells. Modified immunoprecipitation was then performed, where
cells were exposed to biotin in culture, immunoprecipitated with anti-αv, anti-β3, or control IgG, then separated by SDS-PAGE electropho-
resis (B). Bands at the expected location of the αv and β3 integrin subunits (125 and 105 kDa, respectively) are noted when either primary
antibody was used in SKOV3ip1 and HeyA8. Expression in A2780ip2 was not high enough to be detected by this method.
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the combination were all effective in reducing the number of nodules
formed and preventing ascites formation, though combination therapy
was not significantly different compared to either single-agent therapy
in these parameters (data not shown).
In the A2780ip2 model (Figure 2B), different effects of therapy
were noted. Tumor weight after etaracizumab treatment was not sig-
nificantly different from that of IgG-treated tumors. However, when
combined with paclitaxel, treatment significantly reduced tumor
growth by 86.4% compared to control mice (P = .029) and by
72.8% compared to paclitaxel/IgG (P = .14). The striking difference
between response to etaracizumab with and without paclitaxel sug-
gests some mechanism of additional benefit with the combination
in this model.
In the HeyA8 model, a different response pattern was seen (Fig-
ure 2C ). In this model, etaracizumab therapy alone did significantly
reduced tumor weight, by 35.6% (P = .047). However, tumors sub-
jected to combination therapy with etaracizumab and paclitaxel had
comparable weights to etaracizumab alone, that is, 32.3% larger tu-
mors than paclitaxel/IgG (P = .46). These responses suggest that
biologic processes allowing additional benefit in the other models
is absent in the HeyA8 model.
Response to Combination Therapy Can Be Explained by
Dependence on the Akt Pathway
A positive response seen with etaracizumab alone in the SKOV3ip1
and HeyA8 cell lines, but not in A2780ip2 was not surprising, given
the low expression of αvβ3 in A2780ip2. However, an explanation for
the positive response to chemotherapy in this line and SKOV3ip1,
but not HeyA8, was not readily apparent. The HeyA8 cell line con-
tains a BRAF mutation and, therefore, is primarily dependent on
the Ras/Raf/Erk pathway for its proliferative capacity [34]. The
SKOV3ip1 line, conversely, has constitutive activation of Akt, as does
Figure 2. Effect of therapy on tumor growth. Nude mice were injected intraperitoneally with SKOV3ip1 (A), A2780ip2 (B), or HeyA8 (C)
cells. One week after injection, therapy began with control IgG, etaracizumab (eta), paclitaxel (Pac) plus IgG, or etaracizumab plus pac-
litaxel. Antibodies were given twice weekly at a dose of 10 mg/kg, paclitaxel once weekly at a dose of 100 μg, all administered intra-
peritoneally. All animals in an experiment were killed when control animals became moribund from tumor, and total tumor weight was
measured. Mean weights ± SD are shown on the left; individual tumor measurements are shown on the right. Weights between the
two groups were compared with the Student’s t test if values were normally distributed and the Mann-Whitney rank sum test if non-
parametric. Etaracizumab alone was superior to IgG in SKOV3ip1 and HeyA8, the two lines with highest αvβ3 expression. Addition of
etaracizumab to paclitaxel was superior to paclitaxel with IgG in the SKOV3ip1 and A2780ip2 models.
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the A2780ip2 line, which contains a PTEN mutation [35]. Because of
these differences in biology, we examined the effect of etaracizumab
treatment on members of the Akt pathway in SKOV3ip1 and HeyA8.
Cells were incubated with etaracizumab or control IgG in 0.5% FBS
media for 15 minutes, then plated onto vitronectin-coated plates. After
24 hours, cells were harvested as lysate and subjected to Western blot
analysis of phospho-Akt (Figure 3). Although etaracizumab decreased
the degree of p-Akt by 39% in the SKOV3ip1 cells, it did not affect
the barely detectable p-Akt in HeyA8. After membrane stripping and
reprobing for total Akt2 (the predominant Akt isoform in ovarian can-
cer), followed by total Akt1, treatment with etaracizumab actually led
to a decrease in total Akt of both isoforms (36% and 45% reductions,
respectively). Interestingly, etaracizumab led to activation of the 55-kDa
subunit of PI3K, which may be a compensatory response to decreasing
total Akt. Finally, a decrease in Akt phosphorylation was associated with
a decrease in phosphorylated mTOR, a prominent downstream effector
of the Akt pathway. Because the p-Akt signal in HeyA8 at 24 hours
was barely detectable, we repeated the experiment to collect cells after
5 minutes of vitronectin exposure (20 total minutes of etaracizumab
exposure) in serum-free media. This condition lead to activation of
Akt, which was not prevented by etaracizumab. This also confirms that
although Akt is not constitutively activated in HeyA8, it is capable of
being phosphorylated. This profile persisted at 30 minutes, but Akt was
back to near undetectable levels after 4 hours (data not shown). The
mTOR protein is not activated to a significant degree in HeyA8.
Mechanisms of Etaracizumab Effects: Analysis of
Proliferation, Invasion, and Angiogenesis
On the basis of the observed in vivo effects, we next asked whether
etaracizumab could directly inhibit tumor cell proliferation. In vitro,
cells were first plated on uncoated 96-well culture plates with increas-
ing doses of etaracizumab and allowed to proliferate for 5 days, and
cell viability was measured by the MTT assay. Etaracizumab did not
affect proliferation under these conditions (Figure 4A, open bars). Sub-
sequently, the effects of etaracizumab were examined after coating the
tissue culture plates with vitronectin, the primary matrix for αvβ3. At
low doses, vitronectin potentiated cell growth (Figure 4A, closed bars).
However, with treatment of etaracizumab, growth is significantly in-
hibited in a dose-dependent fashion. These data indicate that blocking
αvβ3 has a negative effect on in vitro cell proliferation only if its matrix
receptor is present. In docetaxel sensitivity experiments with concur-
rent treatment with etaracizumab and increasing doses of docetaxel,
etaracizumab did not sensitize SKOV3ip1 or A2780ip2 cells to doce-
taxel (data not shown). This suggests that paclitaxel-sensitizing effects
of etaracizumab in the SKOV3ip1 and A2780ip2 models are depen-
dent on the correct in vivo microenvironment.
To analyze proliferation in vivo, representative tumors collected at
the conclusion of therapy experiments were stained for PCNA. The
percentage of PCNA-positive cells was calculated and shown in
Figure 4B. Etaracizumab, paclitaxel, and combination therapy were
all found to reduce the percentage of proliferating cells by 31% to
45% compared to control IgG-treated samples (P < .05). Combina-
tion therapy was not significantly different from either single-agent
treatment, despite the finding that SKOV3ip1 and A2780ip2 tumors
were smaller with combination therapy.
Because inhibition of αvβ3 integrin can have antiangiogenic effects
by targeting endothelial cells, tumors were then evaluated for micro-
vessel density by staining with CD31. The mean number of vessels
per high-powered field was calculated, and no significant difference
between groups was seen (Figure 4C ). This was not an unexpected
finding, given the lack of recognition of murine αvβ3 integrin that
would be expressed by the host endothelial cells.
On the basis of the potential role of the αvβ3 integrin in cell move-
ment, we next examined the effects of etaracizumab on ovarian can-
cer cell invasion using the MICS. In the presence of increasing doses
of etaracizumab (1 or 10 μg/ml vs 10 μg/ml control human IgG),
the percent of cells invading through the membrane were compared.
In a dose-dependent manner, etaracizumab significantly inhibited
Figure 3. Effects of etaracizumab on the AKT pathway. To explore
an explanation for the differential effects seen in vivo in SKOV3ip1
and HeyA8 despite αvβ3 expression, we examined effects of expo-
sure to etaracizumab on cells plated on vitronectin. Cell lysate
from cells exposed for 24 hours was collected and tested for
phosphorylated Akt (p-Akt), total Akt2 (tot Akt2), total Akt1 (tot
Akt1), phosphorylated PI3 kinase 85-kDa subunit (p-PI3K-85), phos-
phorylated PI3 kinase 55-kDa subunit (p-PI3K-55), phosphorylated
mTOR (p-mTOR), and β-actin (A). Band intensity was quantified
with Scion Image and normalized with β-actin band intensity,
and the change noted with etaracizumab is shown (B). At 24 hours
in the SKOV3ip1 cell line, phosphorylated Akt, total Akt1, and total
Akt2 were all decreased with treatment, as was phosphorylated
mTOR. Interestingly, phosphorylated PI3K–55-kDa subunit was in-
creased with treatment. No treatment effect was seen in HeyA8 at
24 hours, although the pathway was shown to be intact by higher
phosphorylated Akt (in both treatment groups) at 5 minutes, likely
a transient effect due to a change to low-serum media. Phosphory-
lated mTOR was not measurable (NM) in HeyA8 at 5 minutes and
24 hours.
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invasion (Figure 4D). Collectively, these findings indicate a direct in-
hibitory effect of etaracizumab on ovarian cancer cell proliferation
and invasion. No appreciable difference in microvessel density may
be primarily due to a lack of recognition of murine αvβ3 integrin on
tumor endothelial cells by etaracizumab.
Discussion
We have demonstrated that αvβ3 is expressed on ovarian cancer
cell lines and that blocking this integrin with etaracizumab results
in reduced proliferation in vitro and in vivo, reduced invasion, and in-
hibition of tumor growth when used in combination with paclitaxel.
The response to therapy could be predicted by the expression of αvβ3
and dependence on the AKT pathway for each cell line (Table 1).
These data are the first demonstrating in vivo efficacy in an ovarian
cancer model, and offer encouraging evidence that etaracizumab may
be effective in treating ovarian cancer in a clinical setting. Of note,
because the antibody used does not cross-react with murine αvβ3,
these responses represent direct effects on tumor cells. It is possible
that additional antivascular effects from αvβ3 blockade on human en-
dothelial cells may contribute to even greater efficacy in patients.
Although we observed that combination etaracizumab and pacli-
taxel in vivo was superior to single-agent therapy in decreasing tumor
growth in the SKOV3ip1 and A2780ip2 models, such effects were
not observed in vitro. This apparent difference between in vitro and
in vivo effects may be due to an unknown function of the αvβ3 integ-
rin within the tumor microenvironment that sensitizes tumor cells to
chemotherapy and cannot be duplicated in two-dimensional culture
conditions despite the presence of vitronectin. Further elucidation of
such mechanisms, beyond effects on proliferation and angiogenesis, is
Figure 4. Mechanisms of etaracizumab effects on ovarian cancer. In an MTT viability assay, cells were allowed to grow on uncoated
wells or wells precoated with vitronectin, with increasing concentrations of etaracizumab (A). At low concentrations of etaracizumab,
vitronectin promoted cell viability. However, at higher concentrations of etaracizumab, viability was inhibited on cells grown on vitro-
nectin, the αvβ3 receptor. Etaracizumab did not affect viability when wells were not precoated with vitronectin. Data shown is in
SKOV3ip1, with HeyA8 giving similar results. To assess in vivo effects on tumor biology, tumors were collected at the conclusion of
the therapy experiments described in Figure 2 and tested for proliferation index as determined by PCNA positivity (B) and microvessel
density as determined by number of CD31-positive lumens (C). The mean number of PCNA-positive cells or vessels in five randomly
selected fields were counted and compared between groups. Consistent with in vitro proliferation data, etaracizumab (eta) reduced the
proliferation index compared to IgG-exposed tumors, though there was no significant difference between IgG/paclitaxel– (IgG + pac)
and etaracizumab/paclitaxel– (eta + pac) treated tumors. However, all four groups were similar in microvessel density, which may be a
reflection of the lack of recognition of the murine αvβ3 integrin by etaracizumab. Finally, using the MICS, cell invasion through a human
defined matrix in SKOV3ip1 and HeyA8 were examined with and without etaracizumab (D). Blockade of αvβ3 leads to a dose-dependent
inhibition of invasion in both cell lines.
Table 1. Summary of Cell Line Properties and Response to Therapy.
Cell Line αvβ3 Expression Response to
Etaracizumab
p-Akt–Dependent Etaracizumab Increases
Paclitaxel Efficacy
SKOV3ip1 High Yes Yes Yes
A2780ip2 Low No Yes Yes
HeyA8 High Yes No No
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underway and may provide additional insights into the functions of
the αvβ3 integrin.
The αvβ3 integrin is an attractive target for cancer therapy. It is the
primary integrin involved in angiogenesis [5]. Several preclinical
studies have demonstrated effective antitumor effects in targeting
αvβ3 by antibody-mediated or small molecule inhibitor approaches
[11,21–24]. In addition, there is limited expression of αvβ3 on nor-
mal tissues, including minimal expression on intestinal, vascular, and
uterine smooth muscle cells [36], and moderate expression on acti-
vated leukocytes, macrophages, and osteoclasts [37,38]. This favor-
able expression pattern is also supported by the emerging clinical
experience with αvβ3 blockade. For example, in a phase I trial with
etaracizumab [25], no grade 3 to 4 toxicities were noted, though
most patients had grade 1 self-limited fever, chills, and malaise, a re-
action commonly found with immunotherapy. One patient in this
trial had ovarian cancer and had stable disease after 9 weeks of ther-
apy. Prior studies have demonstrated a prolongation in progression-
free survival in consolidation chemotherapy for ovarian carcinoma,
although toxicities were significantly increased [39]. An agent that
retards tumor growth with minimal adverse effects would be ideal
for consolidation or maintenance therapy. Targeting αvβ3, or using
similar antivascular strategies, is an attractive option in this setting.
In ovarian cancer, the αv subunit has been found on 100% (of
30 samples) of ovarian tumors and on cells from effusions in 96%
(of 121 samples) of patients [25], although the expression of the
β3 subunit was not examined. In vitro, migration of ovarian cancer
cells has been found to be dependent on αvβ3 [11]. The αvβ3 integ-
rin mediates adhesion to the ECM [22], and mobility of ovarian can-
cer cells is enhanced by αvβ3 and its interaction with vitronectin
[24]. Inhibition of αvβ3 through enhanced expression of a natural
ligand [40] or through the use of monoclonal antibodies has been
shown to inhibit ovarian cancer cell adhesion, mobility, and migra-
tion [11,40].
There is evidence for a role of αvβ3 in multiple mechanisms of
tumor growth and invasion, including interaction with ECM com-
ponents, matrix metalloproteinase 2, platelet-derived growth factor,
insulin, VEGF receptors, and prevention of apoptosis [33]. This is
of significance not only because there may be redundant pathways
to invasion and angiogenesis that can compensate for blockade of a
single pathway but also because each tumor has different biologic
properties and may be more dependent on one pathway than an-
other. As we have shown, differential key processes such as αvβ3 ex-
pression and dependence on Akt may explain variable response to
therapy and to combination with chemotherapy. Targeting a protein
that inhibits several facets of a pathway that is common to all cancers,
i.e., angiogenesis, would be a favorable method for use in all patients
that may have heterogeneous tumors. However, as we have shown,
even antiangiogenic therapy may have variable responses among het-
erogeneous tumors.
In summary, we have provided evidence for participation of the
αvβ3 integrin in ovarian cancer proliferation and invasion and dem-
onstrate that blocking the integrin with the clinically available
humanized monoclonal antibody etaracizumab can inhibit tumor
growth in an orthotopic mouse model of advanced ovarian cancer.
Response to therapy is variable and is enhanced by dependence of
the cancer cells on the Akt pathway. As development of etaracizumab
continues, consideration should be given to clinical testing in ovarian
cancer and, if effective, would be an attractive agent for use in recur-
rent cancer therapy in combination with chemotherapy. In addition,
because of its low toxicity, this antibody may also be useful in a con-
solidation therapy setting.
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